双極性障害治療薬市場レポート：2030年までの動向、予測、競合分析

双極性障害治療薬の動向と予測

世界の双極性障害治療薬市場は、2024年から2030年にかけてCAGR 3.7％で成長すると予測されます。この市場の主な促進要因は、メンタルヘルスに対する意識の高まりと双極性障害の有病率の上昇です。世界の双極性障害治療薬市場の将来は、経口薬市場と非経口薬市場に機会があり、有望視されています。

双極性障害治療薬のセグメント別推移

本調査では、薬剤クラス別、投与経路別、作用機序別、地域別の双極性障害治療薬の世界市場予測を掲載しています。

双極性障害治療薬市場の洞察

Lucintel社は、精神病症状の症例が増加していることから、予測期間中も抗精神病薬が最大セグメントであり続けると予測しています。

同市場では、経口薬が投与の柔軟性と費用対効果の高さから最大セグメントであり続けると思われます。

北米は、双極性障害の有病率の上昇により、予測期間中最大の地域であり続けるでしょう。

よくある質問

Q1.市場の成長予測は：

A1.世界の双極性障害治療薬市場は、2024年から2030年にかけてCAGR 3.7%で成長すると予想されています。

Q2.市場の成長に影響を与える主な促進要因は：

A2.この市場の主な促進要因は、メンタルヘルスに対する意識の高まりと双極性障害の有病率の上昇です。

Q3.市場の主要セグメントは：

A3.双極性障害治療薬市場の将来は、経口薬市場と非経口薬市場に機会があり、有望です。

Q4.市場の主要企業は：

A4.双極性障害治療薬の主要企業は以下の通り：

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

Q5.今後、最大となる市場セグメントは：

A5.Lucintelは、精神病症状の症例が増加していることから、予測期間中、抗精神病薬が最大のセグメントであり続けると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は：

A6.双極性障害の有病率の上昇により、北米は予測期間中最大の地域であり続けます。

Q7.レポートのカスタマイズは可能か：

A7.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の双極性障害治療薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 双極性障害治療薬の世界市場の動向（2018～2023年）と予測（2024～2030年）
• 薬剤クラス別世界の双極性障害治療薬市場
  • 気分安定剤
  • 抗けいれん薬
  • 抗精神病薬
  • 抗うつ薬
  • 抗不安薬
• 投与経路別世界の双極性障害治療薬市場
  • 経口薬
  • 非経口薬
  • その他
• 作用機序別双極性障害治療薬の世界市場
  • 選択的セロトニン再取り込み阻害剤
  • セロトニン・ノルエピネフリン再取り込み阻害剤
  • 三環系抗うつ薬
  • ベータ遮断薬
  • その他

第4章 2018年から2030年までの地域別市場動向と予測分析

• 地域別世界双極性障害治療薬市場
• 北米の双極性障害治療薬市場
• 欧州の双極性障害治療薬市場
• アジア太平洋地域の双極性障害治療薬市場
• その他地域双極性障害治療薬市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 薬剤クラス別の世界の双極性障害治療薬市場の成長機会
  • 投与経路別の世界の双極性障害治療薬市場の成長機会
  • 作用機序別の世界の双極性障害治療薬市場の成長機会
  • 地域別の世界の双極性障害治療薬市場の成長機会
• 世界の双極性障害治療薬市場における新たな動向
• 戦略分析
  • 新製品の開発
  • 双極性障害治療薬市場の世界のキャパシティ拡大
  • 世界の双極性障害治療薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

Bipolar Disorder and Treatment Trends and Forecast

The future of the global bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets. The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030. The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Bipolar Disorder and Treatment by Segment

The study includes a forecast for the global bipolar disorder and treatment by drug class, route of administration, mechanism of action, and region.

Bipolar Disorder and Treatment Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

• Mood Stabilizer
• Anticonvulsants
• Anti-Psychotic Drugs
• Anti-Depressant Drugs
• Anti-Anxiety Drugs

Bipolar Disorder and Treatment Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

• Oral
• Parenteral
• Others

Bipolar Disorder and Treatment Market by Mechanism of Action [Shipment Analysis by Value from 2018 to 2030]:

• Selective Serotonin Reuptake Inhibitor
• Serotonin Norepinephrine Reuptake Inhibitor
• Tricyclic Antidepressant Drug
• Beta Blockers
• Others

Bipolar Disorder and Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Bipolar Disorder and Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bipolar disorder and treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bipolar disorder and treatment companies profiled in this report include-

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

Bipolar Disorder and Treatment Market Insights

Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Within this market, oral will remain the largest segment due to its enhanced dosing flexibility and cost-effectiveness.

North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Features of the Global Bipolar Disorder and Treatment Market

Market Size Estimates: Bipolar disorder and treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Bipolar disorder and treatment market size by drug class, route of administration, mechanism of action, and region in terms of value ($B).

Regional Analysis: Bipolar disorder and treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug class, route of administration, mechanism of action, and regions for the bipolar disorder and treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bipolar disorder and treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for bipolar disorder and treatment market?

Answer: The global bipolar disorder and treatment market is expected to grow with a CAGR of 3.7% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the bipolar disorder and treatment market?

Answer: The major drivers for this market are rising awareness on mental health and rising prevalence of bipolar disorders.

Q3. What are the major segments for bipolar disorder and treatment market?

Answer: The future of the bipolar disorder and treatment market looks promising with opportunities in the oral and parenteral markets.

Q4. Who are the key bipolar disorder and treatment market companies?

Answer: Some of the key bipolar disorder and treatment companies are as follows:

• GlaxoSmithKline
• Pfizer
• Eli Lily
• AbbVie
• Otsuka Holdings
• AstraZeneca
• Novartis

Q5. Which bipolar disorder and treatment market segment will be the largest in future?

Answer: Lucintel forecasts that anti-psychotic drug will remain the largest segment over the forecast period due to growing cases of psychotic symptoms.

Q6. In bipolar disorder and treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising prevalence of bipolar disorders.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the bipolar disorder and treatment market by drug class (mood stabilizer, anticonvulsants, anti-psychotic drugs, anti-depressant drugs, and anti-anxiety drugs), route of administration (oral, parenteral, and others), mechanism of action (selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, tricyclic antidepressant drug, beta blockers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Bipolar Disorder and Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Bipolar Disorder and Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Bipolar Disorder and Treatment Market by Drug Class
  • 3.3.1: Mood Stabilizer
  • 3.3.2: Anticonvulsants
  • 3.3.3: Anti-Psychotic Drugs
  • 3.3.4: Anti-Depressant Drugs
  • 3.3.5: Anti-Anxiety Drugs
• 3.4: Global Bipolar Disorder and Treatment Market by Route of Administration
  • 3.4.1: Oral
  • 3.4.2: Parenteral
  • 3.4.3: Others
• 3.5: Global Bipolar Disorder and Treatment Market by Mechanism of Action
  • 3.5.1: Selective Serotonin Reuptake Inhibitor
  • 3.5.2: Serotonin Norepinephrine Reuptake Inhibitor
  • 3.5.3: Tricyclic Antidepressant Drug
  • 3.5.4: Beta Blockers
  • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Bipolar Disorder and Treatment Market by Region
• 4.2: North American Bipolar Disorder and Treatment Market
  • 4.2.1: North American Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.2.2: North American Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
• 4.3: European Bipolar Disorder and Treatment Market
  • 4.3.1: European Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.3.2: European Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
• 4.4: APAC Bipolar Disorder and Treatment Market
  • 4.4.1: APAC Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.4.2: APAC Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others
• 4.5: ROW Bipolar Disorder and Treatment Market
  • 4.5.1: ROW Bipolar Disorder and Treatment Market by Drug Class: Mood Stabilizer, Anticonvulsants, Anti-Psychotic Drugs, Anti-Depressant Drugs, and Anti-Anxiety Drugs
  • 4.5.2: ROW Bipolar Disorder and Treatment Market by Route of Administration: Oral, Parenteral, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Drug Class
  • 6.1.2: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Route of Administration
  • 6.1.3: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Mechanism of Action
  • 6.1.4: Growth Opportunities for the Global Bipolar Disorder and Treatment Market by Region
• 6.2: Emerging Trends in the Global Bipolar Disorder and Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Bipolar Disorder and Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bipolar Disorder and Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GlaxoSmithKline
• 7.2: Pfizer
• 7.3: Eli Lily
• 7.4: AbbVie
• 7.5: Otsuka Holdings
• 7.6: AstraZeneca
• 7.7: Novartis